3 results
Approved WMOCompleted
To evaluate the effect of MEDI6012 on infarct size compared with placebo.
Approved WMOWill not start
Phase 1b Dose Escalation Objectives • To determine the safety and tolerability of escalating doses of GB5121• To determine the optimal biological dose (OBD) and/or maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of GB5121 Phase 1b…
Approved WMORecruiting
Primary objectivesPart 1 Dose Escalation for LAVA-1207 alone, LAVA-1207 plus LDSC IL-2, and LAVA-1207 plus pembrolizumab• To investigate the safety and tolerability of treatment in patients with therapy refractory mCRPC.• To determine the…